CA3165243A1 - Crystalline aclidinium bromide and uses thereof - Google Patents

Crystalline aclidinium bromide and uses thereof Download PDF

Info

Publication number
CA3165243A1
CA3165243A1 CA3165243A CA3165243A CA3165243A1 CA 3165243 A1 CA3165243 A1 CA 3165243A1 CA 3165243 A CA3165243 A CA 3165243A CA 3165243 A CA3165243 A CA 3165243A CA 3165243 A1 CA3165243 A1 CA 3165243A1
Authority
CA
Canada
Prior art keywords
aclidinium bromide
pharmaceutical composition
crystalline
mixture
bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3165243A
Other languages
English (en)
French (fr)
Inventor
Zita Mendes
Constanca Cacela
Bruno SANTOS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Scientia Ltd
Original Assignee
Hovione Scientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Scientia Ltd filed Critical Hovione Scientia Ltd
Publication of CA3165243A1 publication Critical patent/CA3165243A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0018—Evaporation of components of the mixture to be separated
    • B01D9/0027—Evaporation of components of the mixture to be separated by means of conveying fluid, e.g. spray-crystallisation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Catalysts (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
CA3165243A 2015-03-30 2016-03-30 Crystalline aclidinium bromide and uses thereof Pending CA3165243A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT10837015A PT108370B (pt) 2015-03-30 2015-03-30 Processo de preparação de brometo de aclidínio
PT108370 2015-03-30
CA2980665A CA2980665A1 (en) 2015-03-30 2016-03-30 Process for the preparation of aclidinium bromide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2980665A Division CA2980665A1 (en) 2015-03-30 2016-03-30 Process for the preparation of aclidinium bromide

Publications (1)

Publication Number Publication Date
CA3165243A1 true CA3165243A1 (en) 2016-10-06

Family

ID=55806548

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3165243A Pending CA3165243A1 (en) 2015-03-30 2016-03-30 Crystalline aclidinium bromide and uses thereof
CA2980665A Pending CA2980665A1 (en) 2015-03-30 2016-03-30 Process for the preparation of aclidinium bromide

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2980665A Pending CA2980665A1 (en) 2015-03-30 2016-03-30 Process for the preparation of aclidinium bromide

Country Status (9)

Country Link
US (2) US10087177B2 (enExample)
EP (1) EP3277679A1 (enExample)
JP (4) JP2018510189A (enExample)
CN (1) CN108112252B (enExample)
AU (1) AU2016240289B2 (enExample)
CA (2) CA3165243A1 (enExample)
IL (1) IL254712A0 (enExample)
PT (1) PT108370B (enExample)
WO (1) WO2016156836A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
CN108586450B (zh) * 2017-12-15 2021-02-19 上海方予健康医药科技有限公司 一种胆碱m受体抗结剂的重结晶纯化方法
PT115583B (pt) * 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN114890997A (zh) * 2022-04-20 2022-08-12 江苏联环药业股份有限公司 一种抗胆碱能药物噻格溴铵的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
PT1651270E (pt) * 2003-07-29 2007-04-30 Boehringer Ingelheim Int Medicamentos para inalação compreendendo betamiméticos e um anticolinérgico
LT1993360T (lt) * 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
JP6389174B2 (ja) * 2012-08-15 2018-09-12 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 化学的方法
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
WO2015071824A1 (en) 2013-11-13 2015-05-21 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of aclidinium bromide
PT108370B (pt) 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio

Also Published As

Publication number Publication date
US10087177B2 (en) 2018-10-02
JP2021020965A (ja) 2021-02-18
EP3277679A1 (en) 2018-02-07
US10590124B2 (en) 2020-03-17
JP2018510189A (ja) 2018-04-12
IL254712A0 (en) 2017-11-30
JP2022160667A (ja) 2022-10-19
AU2016240289A1 (en) 2017-10-19
JP2020143160A (ja) 2020-09-10
CN108112252A (zh) 2018-06-01
PT108370B (pt) 2018-10-25
CN108112252B (zh) 2020-11-24
WO2016156836A1 (en) 2016-10-06
JP7124035B2 (ja) 2022-08-23
US20180362523A1 (en) 2018-12-20
AU2016240289B2 (en) 2020-08-27
US20180105517A1 (en) 2018-04-19
PT108370A (pt) 2016-09-30
CA2980665A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP7124035B2 (ja) アクリジニウム臭化物の製造方法
CN104144928B (zh) 制备噻托溴铵的方法
EP2882753B1 (en) Process for the preparation of pemetrexed and lysin salt thereof
JP2018510189A5 (enExample)
CN108586450B (zh) 一种胆碱m受体抗结剂的重结晶纯化方法
JP2014201592A (ja) 臭化チオトロピウムの結晶形態
JP2012500268A (ja) ７−クロロ−Ｎ，Ｎ，５−トリメチル−４−オキソ−３−フェニル−３，５−ジヒドロ−４Ｈ−ピリダジノ［４，５−ｂ］インドール−１−アセトアミドの多形体を製造するための方法
EP3052499B1 (en) Crystalline abacavir hydrochloride monohydrate and process for its preparation
CN119859139A (zh) 双盐酸安罗替尼的固体形式及其制备方法
HK1209426B (en) Process for the preparation of pemetrexed and lysin salt thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220623